Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis

References

• Aktas O Küry P Kieseier B Hartung HP Fingolimod is a potential novel therapy for multiple sclerosis Nat Rev Neurol 2010 6 7 373 382 20551946
   PubMed Web of Science ®Google Scholar
• Cohen JA Barkhof F Comi G TRANSFORMS Study Group Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 2010 362 5 402 415 20089954
   PubMed Web of Science ®Google Scholar
• Kappos L Radue EW O’Connor P FREEDOMS Study Group A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 2010 362 5 387 401 20089952
   PubMed Web of Science ®Google Scholar
• Chun J Hartung HP Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin Neuropharmacol 2010 33 2 91 101 20061941
   PubMed Web of Science ®Google Scholar
• Boujaoude LC Bradshaw-Wilder C Mao C Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate J Biol Chem 2001 276 38 35258 35264 11443135
   PubMed Web of Science ®Google Scholar
• Kobayashi N Nishi T Hirata T Sphingosine 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated manner J Lipid Res 2006 47 3 614 621 16371645
   PubMed Web of Science ®Google Scholar
• Mitra P Oskeritzian CA Payne SG Beaven MA Milstien S Spiegel S Role of ABCC1 in export of sphingosine-1-phosphate from mast cells Proc Natl Acad Sci U S A 2006 103 44 16394 16399 17050692
   PubMed Web of Science ®Google Scholar
• Rivera J Proia RL Olivera A The alliance of sphingosine-1-phosphate and its receptors in immunity Nat Rev Immunol 2008 8 10 753 763 18787560
   PubMed Web of Science ®Google Scholar
• David OJ Kovarik JM Schmouder RL Clinical pharmacokinetics of fingolimod Clin Pharmacokinet 2012 51 1 15 28 22149256
   PubMed Web of Science ®Google Scholar
• Arnon TI Xu Y Lo C GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood Science 2011 333 6051 1898 1903 21960637
   PubMed Web of Science ®Google Scholar
• Mrowietz U Asadullah K Dimethylfumarate for psoriasis: more than a dietary curiosity Trends Mol Med 2005 11 1 43 48 15649822
   PubMed Web of Science ®Google Scholar
• Rostami-Yazdi M Mrowietz U Fumaric acid esters Clin Dermatol 2008 26 5 522 526 18755371
   PubMed Web of Science ®Google Scholar
• Gold R Kappos L Arnold DL DEFINE Study Investigators Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med 2012 367 12 1098 1107 Erratum in: N Engl J Med. 2012;367(24):2362 22992073
   PubMed Web of Science ®Google Scholar
• Fox RJ Miller DH Phillips JT CONFIRM Study Investigators Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N Engl J Med 2012 367 12 1087 1097 Erratum in: N Engl J Med. 2012;367(17):1673 22992072
   PubMed Web of Science ®Google Scholar
• Scannevin RH Chollate S Jung MY Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway J Pharmacol Exp Ther 2012 341 1 274 284 22267202
   PubMed Web of Science ®Google Scholar
• Ashrafian H Czibik G Bellahcene M Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway Cell Metab 2012 15 3 361 371 22405071
   PubMed Web of Science ®Google Scholar
• Itoh K Chiba T Takahashi S An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements Biochem Biophys Res Commun 1997 236 2 313 322 9240432
   PubMed Web of Science ®Google Scholar
• Venugopal R Jaiswal AK Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes Oncogene 1998 17 24 3145 3156 9872330
   PubMed Web of Science ®Google Scholar
• Lin SX Lisi L Dello Russo C The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1 ASN Neuro 2011 3 2 75 84
   Web of Science ®Google Scholar
• Wakabayashi N Slocum SL Skoko JJ Shin S Kensler TW When NRF2 talks, who’s listening? Antioxid Redox Signal 2010 13 11 1649 1663 20367496
   PubMed Web of Science ®Google Scholar
• Brigelius-Flohé R Flohé L Basic principles and emerging concepts in the redox control of transcription factors Antioxid Redox Signal 2011 15 8 2335 2381 21194351
   PubMed Web of Science ®Google Scholar
• Ji L Li H Gao P Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer PLoS One 2013 8 5 e63404 23667609
   PubMed Web of Science ®Google Scholar
• Kensler TW Wakabayashi N Nrf2: friend or foe for chemoprevention? Carcinogenesis 2010 31 1 90 99 19793802
   PubMed Web of Science ®Google Scholar
• Comi G Jeffery D Kappos L ALLEGRO Study Group Placebo-controlled trial of oral laquinimod for multiple sclerosis N Engl J Med 2012 366 11 1000 1009 22417253
   PubMed Web of Science ®Google Scholar
• Schwarcz R Bruno JP Muchowski PJ Wu HQ Kynurenines in the mammalian brain: when physiology meets pathology Nat Rev Neurosci 2012 13 7 465 777 22678511
   PubMed Web of Science ®Google Scholar
• Hönig A Rieger L Kapp M Sütterlin M Dietl J Kämmerer U Indoleamine 2,3-dioxygenase (IDO) expression in invasive extravillous trophoblast supports role of the enzyme for materno-fetal tolerance J Reprod Immunol 2004 61 2 79 86 15063631
   PubMed Web of Science ®Google Scholar
• Fallarino F Vacca C Orabona C Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells Int Immunol 2002 14 1 65 68 11751753
   PubMed Web of Science ®Google Scholar
• Frumento G Rotondo R Tonetti M Damonte G Benatti U Ferrara GB Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase J Exp Med 2002 196 4 459 468 12186838
   PubMed Web of Science ®Google Scholar
• Belladonna ML Grohmann U Guidetti P Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO J Immunol 2006 177 1 130 137 16785507
   PubMed Web of Science ®Google Scholar
• Chen Y Meininger V Guillemin GJ Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors Cent Nerv Syst Agents Med Chem 2009 9 1 32 39 20021336
   PubMedGoogle Scholar
• Killestein J Rudick RA Polman CH Oral treatment for multiple sclerosis Lancet Neurol 2011 10 11 1026 1034 22014437
   PubMed Web of Science ®Google Scholar
• O’Connor P Wolinsky JS Confavreux C TEMSO Trial Group Randomized trial of oral teriflunomide for relapsing multiple sclerosis N Engl J Med 2011 365 14 1293 1303 21991951
   PubMed Web of Science ®Google Scholar
• Greene S Watanabe K Braatz-Trulson J Lou L Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide Biochem Pharmacol 1995 50 6 861 867 7575649
   PubMed Web of Science ®Google Scholar
• Williamson RA Yea CM Robson PA Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound J Biol Chem 1995 270 38 22467 22472 7673235
   PubMed Web of Science ®Google Scholar
• Fox RI Herrmann ML Frangou CG Mechanism of action for leflunomide in rheumatoid arthritis Clin Immunol 1999 93 3 198 208 10600330
   PubMed Web of Science ®Google Scholar
• Claussen MC Korn T Immune mechanisms of new therapeutic strategies in MS: teriflunomide Clin Immunol 2012 142 1 49 56 21367665
   PubMed Web of Science ®Google Scholar
• Siemasko K Chong AS Jäck HM Gong H Williams JW Finnegan A Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production J Immunol 1998 160 4 1581 1588 9469413
   PubMed Web of Science ®Google Scholar
• González-Alvaro I Ortiz AM Domínguez-Jiménez C Aragón-Bodi A Díaz Sánchez B Sánchez-Madrid R Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway Ann Rheum Dis 2009 68 10 1644 1650 18957484
   PubMed Web of Science ®Google Scholar
• Mattar T Kochhar K Bartlett R Bremer EG Finnegan A Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide FEBS Lett 1993 334 2 161 164 8224241
   PubMed Web of Science ®Google Scholar
• Hamilton LC Vojnovic I Warner TD A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner Br J Pharmacol 1999 127 7 1589 1596 10455314
   PubMed Web of Science ®Google Scholar
• Cohen JA Chun J Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis Ann Neurol 2011 69 5 759 777 21520239
   PubMed Web of Science ®Google Scholar
• Kivisäkk P Mahad DJ Callahan MK Expression of CCR7 in multiple sclerosis: implications for CNS immunity Ann Neurol 2004 55 5 627 638 15122702
   PubMed Web of Science ®Google Scholar
• Brinkmann V Billich A Baumruker T Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat Rev Drug Discov 2010 9 11 883 897 21031003
   PubMed Web of Science ®Google Scholar
• Cyster JG Schwab SR Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs Annu Rev Immunol 2012 30 69 94 22149932
   PubMed Web of Science ®Google Scholar
• Hla T Brinkmann V Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation Neurology 2011 76 8 Suppl 3 S3 S8 21339489
   PubMed Web of Science ®Google Scholar
• Matloubian M Lo CG Cinamon G Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 Nature 2004 427 6972 355 360 14737169
   PubMed Web of Science ®Google Scholar
• Sallusto F Mackay CR Chemoattractants and their receptors in homeostasis and inflammation Curr Opin Immunol 2004 16 6 724 731 15511664
   PubMed Web of Science ®Google Scholar
• Brinkmann V FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system Br J Pharmacol 2009 158 5 1173 1182 19814729
   PubMed Web of Science ®Google Scholar
• Oo ML Thangada S Wu MT Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor J Biol Chem 2007 282 12 9082 9089 17237497
   PubMed Web of Science ®Google Scholar
• Liu G Burns S Huang G The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR Nat Immunol 2009 10 7 769 777 19483717
   PubMed Web of Science ®Google Scholar
• Liu G Yang K Burns S Shrestha S Chi H The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells Nat Immunol 2010 11 11 1047 1056 20852647
   PubMed Web of Science ®Google Scholar
• Sun Y Wang W Shan B FTY720-induced conversion of conventional Foxp3- CD4+ T cells to Foxp3+ regulatory T cells in NOD mice Am J Reprod Immunol 2011 66 5 349 362 21623989
   PubMed Web of Science ®Google Scholar
• Daniel C Sartory N Zahn N Geisslinger G Radeke HH Stein JM FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells J Immunol 2007 178 4 2458 2468 17277153
   PubMed Web of Science ®Google Scholar
• Kim HJ Miron VE Dukala D Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model FASEB J 2011 25 5 1509 1518 21248243
   PubMed Web of Science ®Google Scholar
• Mehling M Lindberg R Raulf F Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis Neurology 2010 75 5 403 410 20592255
   PubMed Web of Science ®Google Scholar
• Treumer F Zhu K Gläser R Mrowietz U Dimethyl fumarate is a potent inducer of apoptosis in human T cells J Invest Dermatol 2003 121 6 1383 1388 14675187
   PubMed Web of Science ®Google Scholar
• Mrowietz U Asadullah K Dimethyl fumarate for psoriasis: more than a dietary curiosity Trends Mol Med 2005 11 1 43 48 15649822
   PubMed Web of Science ®Google Scholar
• Ormerod AD Mrowietz U Fumaric acid esters, their place in the treatment of psoriasis Br J Dermatol 2004 150 4 630 632 15099356
   PubMed Web of Science ®Google Scholar
• Albrecht P Bouchachia I Goebels N Effects of dimethyl fumarate on neuroprotection and immunomodulation J Neuroinflammation 2012 9 163 172 22769044
   PubMed Web of Science ®Google Scholar
• Peng H Guerau-de-Arellano M Mehta VB Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling J Biol Chem 2012 287 33 28017 28026 22733812
   PubMed Web of Science ®Google Scholar
• Ghoreschi K Brück J Kellerer C Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells J Exp Med 2011 208 11 2291 2303 21987655
   PubMed Web of Science ®Google Scholar
• Brück W Wegner C Insight into the mechanism of laquinimod action J Neurol Sci 2011 306 1–2 173 179 21429524
   PubMed Web of Science ®Google Scholar
• Toubi E Nussbaum S Staun-Ram E Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis J Neuroimmunol 2012 251 1–2 45 54 22846497
   PubMed Web of Science ®Google Scholar
• Gurevich M Gritzman T Orbach R Tuller T Feldman A Achiron A Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study J Neuroimmunol 2010 221 1–2 87 94 20347159
   PubMed Web of Science ®Google Scholar
• Zou LP Abbas N Volkmann I Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue Neuropharmacol 2002 42 5 731 739
   PubMed Web of Science ®Google Scholar
• Wegner C Stadelmann C Pförtner R Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis J Neuroimmunol 2010 227 1–2 133 143 20684995
   PubMed Web of Science ®Google Scholar
• Aharoni R Saada R Eilam R Hayardeny L Sela M Arnon R Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis J Neuroimmunol 2012 251 1–2 14 24 22749337
   PubMed Web of Science ®Google Scholar
• Schulze-Topphoff U Shetty A Varrin-Doyer M Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity PLoS One 2012 7 3 e33797 22479444
   PubMed Web of Science ®Google Scholar
• Layseca-Espinosa E Pedraza-Alva G Montiel JL T cell aggregation induced through CD43: intracellular signals and inhibition by the immunomodulatory drug leflunomide J Leukoc Biol 2003 74 6 1083 1093 12972508
   PubMed Web of Science ®Google Scholar
• Zeyda M Poglitsch M Geyeregger R Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation Arthritis Rheum 2005 52 9 2730 2739 16142756
   PubMed Web of Science ®Google Scholar
• Quéméneur L Gerland LM Flacher M Ffrench M Revillard JP Genestier L Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides J Immunol 2003 170 10 4986 4995 12734342
   PubMed Web of Science ®Google Scholar
• Dimitrova P Skapenko A Herrmann ML Schleyerbach R Kalden JR Schulze-Koops H Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation J Immunol 2002 169 6 3392 3399 12218161
   PubMed Web of Science ®Google Scholar
• Wang L Chiang ET Simmons JT Garcia JG Dudek SM FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl Eur Respir J 2011 38 1 78 88 21071472
   PubMed Web of Science ®Google Scholar
• Sanchez T Skoura A Wu MT Casserly B Harrington EO Hla T Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN Arterioscler Thromb Vasc Biol 2007 27 6 1312 1318 17431187
   PubMed Web of Science ®Google Scholar
• Niessen F Furlan-Freguia C Fernández JA Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality Blood 2009 113 12 2859 2866 19141861
   PubMed Web of Science ®Google Scholar
• Balatoni B Storch MK Swoboda EM FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis Brain Res Bull 2007 74 5 307 316 17845905
   PubMed Web of Science ®Google Scholar
• Foster CA Mechtcheriakova D Storch MK FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage Brain Pathol 2009 19 2 254 266 18540945
   PubMed Web of Science ®Google Scholar
• Miron VE Hall JA Kennedy TE Soliven B Antel JP Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod Am J Pathol 2008 173 4 1143 1152 18772343
   PubMed Web of Science ®Google Scholar
• van Doorn R Nijland PG Dekker N Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes Acta Neuropathol 2012 124 3 397 410 22810490
   PubMed Web of Science ®Google Scholar
• Cannon RE Peart JC Hawkins BT Campos CR Miller DS Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain Proc Natl Acad Sci U S A 2012 109 39 15930 15935 22949658
   PubMed Web of Science ®Google Scholar
• Cartwright TA Campos CR Cannon RE Miller DS Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers J Cereb Blood Flow Metab 2013 33 3 381 388 23168528
   PubMed Web of Science ®Google Scholar
• Jain N Bhatti MT Fingolimod-associated macular edema: incidence, detection, and management Neurology 2012 78 9 672 680 22371414
   PubMed Web of Science ®Google Scholar
• Loewe R Holnthoner W Gröger M Dimethyl fumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells J Immunol 2002 168 9 4781 4787 11971029
   PubMed Web of Science ®Google Scholar
• Meissner M Doll M Hrgovic I Suppression of VEGFR2 expression in human endothelial cells by dimethyl fumarate treatment: evidence for anti-angiogenic action J Invest Dermatol 2011 131 6 1356 1364 21430706
   PubMed Web of Science ®Google Scholar
• Soliven B Miron V Chun J The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators Neurology 2011 76 8 Suppl 3 S9 S14 21339490
   PubMed Web of Science ®Google Scholar
• Van Doorn R Van Horssen J Verzijl D Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions Glia 2010 58 12 1465 1476 20648639
   PubMed Web of Science ®Google Scholar
• Choi JW Gardell SE Herr DR FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation Proc Natl Acad Sci U S A 2011 108 2 751 756 21177428
   PubMed Web of Science ®Google Scholar
• Deogracias R Yazdani M Dekkers MP Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome Proc Natl Acad Sci U S A 2012 109 35 14230 14235 22891354
   PubMed Web of Science ®Google Scholar
• Di Menna L Molinaro G Di Nuzzo L Fingolimod protects cultured cortical neurons against excitotoxic death Pharmacol Res 2013 67 1 1 9 23073075
   PubMed Web of Science ®Google Scholar
• Czech B Pfeilschifter W Mazaheri-Omrani N The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia Biochem Biophys Res Commun 2009 389 2 251 256 19720050
   PubMed Web of Science ®Google Scholar
• Hasegawa Y Suzuki H Sozen T Rolland W Zhang JH Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats Stroke 2010 41 2 368 374 19940275
   PubMed Web of Science ®Google Scholar
• Wei Y Yemisci M Kim HH Fingolimod provides long-term protection in rodent models of cerebral ischemia Ann Neurol 2011 69 1 119 129 21280082
   PubMed Web of Science ®Google Scholar
• Doi Y Takeuchi H Horiuchi H 85. Fingolimod phosphate attenuates oligomeric amyloid β-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons PLoS One 2013 8 4 e61988 23593505
   PubMed Web of Science ®Google Scholar
• Molendijk ML Bus BA Spinhoven P A systematic review and meta-analysis on the association between BDNF val(66)met and hippocampal volume: a genuine effect or a winners curse? Am J Med Genet B Neuropsychiatr Genet 2012 159B 6 731 740 22815222
   PubMed Web of Science ®Google Scholar
• Kanellopoulos D Gunning FM Morimoto SS Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression Am J Geriatr Psychiatry 2011 19 1 13 22 21218562
   PubMed Web of Science ®Google Scholar
• Erickson KI Prakash RS Voss MW Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume J Neurosci 2010 30 15 5368 5375 20392958
   PubMed Web of Science ®Google Scholar
• Benjamin S McQuoid DR Potter GG The brain-derived neurotrophic factor Val66Met polymorphism, hippocampal volume, and cognitive function in geriatric depression Am J Geriatr Psychiatry 2010 18 4 323 331 20220593
   PubMed Web of Science ®Google Scholar
• Neto FL Borges G Torres-Sanchez S Mico JA Berrocoso E Neurotrophins role in depression neurobiology: a review of basic and clinical evidence Curr Neuropharmacol 2011 9 4 530 552 22654714
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM Wolf J Shelly W Serum BDNF levels before treatment predict SSRI response in depression Prog Neuropsychopharmacol Biol Psychiatry 2011 35 7 1623 1630 21749907
   PubMed Web of Science ®Google Scholar
• Yu H Wang DD Wang Y Liu T Lee FS Chen ZY Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants J Neurosci 2012 32 12 4092 4101 22442074
   PubMed Web of Science ®Google Scholar
• Coelho RP Payne SG Bittman R Spiegel S Sato-Bigbee C The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors J Pharmacol Exp Ther 2007 323 2 626 635 17726159
   PubMed Web of Science ®Google Scholar
• Jung CG Kim HJ Miron VE Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells Glia 2007 55 16 1656 1667 17876806
   PubMed Web of Science ®Google Scholar
• Miron VE Jung CG Kim HJ Kennedy TE Soliven B Antel JP FTY720 modulates human oligodendrocyte progenitor process extension and survival Ann Neurol 2008 63 1 61 71 17918267
   PubMed Web of Science ®Google Scholar
• Bieberich E There is more to a lipid than just being a fat: sphingolipid-guided differentiation of oligodendroglial lineage from embryonic stem cells Neurochem Res 2011 36 9 1601 1611 21136155
   PubMed Web of Science ®Google Scholar
• Hu Y Lee X Ji B Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo Mol Cell Neurosci 2011 48 1 72 81 21740973
   PubMed Web of Science ®Google Scholar
• Miron VE Ludwin SK Darlington PJ Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices Am J Pathol 2010 176 6 2682 2694 20413685
   PubMed Web of Science ®Google Scholar
• Jackson SJ Giovannoni G Baker D Fingolimod modulates microglial activation to augment markers of remyelination J Neuroinflammation 2011 8 76 21729281
   PubMed Web of Science ®Google Scholar
• Kipp M Amor S FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination Mult Scler 2012 18 3 258 263 22383435
   PubMed Web of Science ®Google Scholar
• Vladimirova O O’Connor J Cahill A Alder H Butunoi C Kalman B Oxidative damage to DNA in plaques of MS brains Mult Scler 1998 4 5 413 418 9839301
   PubMed Web of Science ®Google Scholar
• Smith KJ McDonald WI The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease Philos Trans R Soc Lond B Biol Sci 1999 354 1390 1649 1473 10603618
   PubMed Web of Science ®Google Scholar
• Lee DH Gold R Linker RA Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters Int J Mol Sci 2012 13 9 11783 11803 23109883
   PubMed Web of Science ®Google Scholar
• Wilms H Sievers J Rickert U Rostami-Yazdi M Mrowietz U Lucius R Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation J Neuroinflammation 2010 7 30 20482831
   PubMed Web of Science ®Google Scholar
• Schmidt MM Dringen R Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione Neurochem Int 2010 57 4 460 467 20096739
   PubMed Web of Science ®Google Scholar
• Thiessen A Schmidt MM Dringen R Fumaric acid dialkyl esters deprive cultured rat oligodendroglial cells of glutathione and upregulate the expression of heme oxygenase 1 Neurosci Lett 2010 475 1 56 60 20347008
   PubMed Web of Science ®Google Scholar
• Moharregh-Khiabani D Blank A Skripuletz T Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse PLoS One 2010 5 7 e11769 20668697
   PubMed Web of Science ®Google Scholar
• Ruffini F Rossi S Bergamaschi A Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis Mult Scler 2012 19 8 1084 1094 23232603
   PubMed Web of Science ®Google Scholar
• Raasch J Zeller N van Loo G IkappaB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappaB in the central nervous system Brain 2011 134 Pt 4 1184 1198 21310728
   PubMed Web of Science ®Google Scholar